• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vera Therapeutics Inc Cl A (NQ: VERA )

    47.70 +2.53 (+5.60%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vera Therapeutics Inc Cl A

    < Previous 1 2 3 4 5 6 7 Next >
    Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
    Vera Therapeutics announces ORIGIN Phase 2b trial data on atacicept, showing sustained IgAN improvement and kidney function stability over 96 weeks. 
    Via Benzinga
    PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug
    The company is working on a treatment for IgA nephropathy, a condition that affects how well the kidneys work. 
    Via Investor's Business Daily
    Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Vera Therapeutics to Participate at September Investor Conferences
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024
    VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Vera Therapeutics
    Via GlobeNewswire
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market
    U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home prices hit record highs. 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
    NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
    From Vera Therapeutics
    Via GlobeNewswire
    VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024
    VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.